ADAR1 affects HCV infection by modulating innate immune response

Area of Science:

• Immunology
• Virology
• Genetics

Background:

• Hepatitis C virus (HCV) causes chronic infections in 80% of cases, evading innate immunity.
• Interferon (IFN) therapy response varies, indicating HCV's immune evasion strategies.
• Adenosine deaminase acting on RNA 1 (ADAR1) is crucial for regulating innate immune responses.

Purpose of the Study:

• To investigate the role of ADAR1 in regulating innate and antiviral immune function during HCV infection.
• To determine the association of ADAR1 gene polymorphisms with clinical outcomes in HCV-infected patients.

Main Methods:

• In vitro studies using primary macrophages and Huh7 hepatoma cells with ADAR1 knockdown.
• Analysis of ADAR1 gene polymorphisms in a cohort of HCV and HIV-1 coinfected patients.
• Assessment of IFN and IFN-stimulated gene expression and HCV replication.

Main Results:

• ADAR1 loss of function leads to aberrant RNA sensor (MDA5, RIG-I) mediated innate immune responses.
• ADAR1 gene polymorphisms correlate with poor HCV therapy outcomes and advanced liver fibrosis.
• ADAR1 knockdown in vitro enhances IFN expression but paradoxically increases HCV replication.

Conclusions:

• ADAR1 is a key regulator of innate immune signaling in HCV infection.
• ADAR1 influences the outcome of HCV virus-host interactions.
• ADAR1 represents a potential therapeutic target for enhancing antiviral immunity against HCV.